Phaseline

Companies › Chengdu New Radiomedicine Technology

Chengdu New Radiomedicine Technology: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NRT6003 Injection
Yttrium-90 radioembolization using carbon microspheres
–Phase 3Unresectable Hepatocellular CarcinomaOct 2027
177Lu-NRT6020 Injection
FAP-targeting radiopharmaceutical for radionuclide therapy
FAPPhase 1Solid Tumor MalignancyOct 2027
68Ga-NRT6020 Injection
FAP-targeting radiopharmaceutical for PET imaging
FAPPhase 1Solid Tumor MalignancyOct 2027
NRT6008–Phase 1Unresectable Pancreatic CancerDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT0691148968Ga-NRT6020 InjectionPhase 1Solid Tumor MalignancyOncologyOct 2027
NCT06911489177Lu-NRT6020 InjectionPhase 1Solid Tumor MalignancyOncologyOct 2027
NCT06900543NRT6003 InjectionPhase 3Unresectable Hepatocellular CarcinomaOncologyOct 2027
NCT06278454NRT6008Phase 1Unresectable Pancreatic CancerOncologyDec 2027

Targets

FAP (2)

Companies with the same targets

Avacta Life Sciences Blue Earth Diagnostics Novartis Ratio Therapeutics Beijing Biotech SOFIE Philogen BioInvent International Lantheus Medical Imaging Perspective Therapeutics

Companies built like this

Blue Earth Diagnostics SOFIE Lantheus Medical Imaging Immunome Nanjing Sanhome Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.